Clinical Trial Update: Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of temsirolimus (Torisel) plus erlotinib (Tarceva) in platinum-refractory/ineligible advanced squamous cell carcinoma was terminated, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma

Drugs mentioned

• Tarceva (erlotinib)
• Torisel (Temsirolimus)

Snippet

Sponsor: New Mexico Cancer Research Alliance | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2015-08-10